그라니세트론 염기 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

The future of the global granisetron base market looks promising with opportunities in the hospital and pharmacy markets. The global granisetron base market is expected to reach an estimated $172.5 million by 2035 with a CAGR of 6.5% from 2026 to 2035. The major drivers for this market are the increasing prevalence of chemotherapy, the rising demand for effective antiemetic treatments, and the growing adoption of supportive cancer care therapies.

• Lucintel forecasts that, within the type category, capsule is expected to witness higher growth over the forecast period.
• Within the application category, hospital is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Granisetron Base Market

The granisetron base market is experiencing a significant transformation driven by technological advancements, changing healthcare needs, and evolving regulatory landscapes. As the demand for effective antiemetic solutions increases, market players are innovating to improve product efficacy, safety, and accessibility. These developments are not only expanding the market scope but also reshaping competitive dynamics and patient care standards. Understanding these emerging trends is crucial for stakeholders aiming to capitalize on growth opportunities and navigate potential challenges in this evolving landscape.

• Increasing Adoption of Generic Granisetron Products: The market is witnessing a surge in generic formulations, driven by patent expirations and cost-containment efforts. This trend enhances accessibility for a broader patient population, reduces treatment costs, and intensifies competition among manufacturers. As generic options become more prevalent, brand-name drugs face pricing pressures, prompting innovation and strategic positioning. The increased availability of affordable alternatives is expected to expand market reach, especially in emerging economies, while also encouraging manufacturers to focus on quality and regulatory compliance to maintain market share.
• Rising Focus on Injectable and Transdermal Delivery Systems: There is a growing preference for alternative delivery methods such as injectables and transdermal patches, which offer improved convenience, faster onset of action, and better patient compliance. Advances in drug delivery technology are enabling more effective formulations that reduce side effects and enhance therapeutic outcomes. This trend is particularly significant in hospital and outpatient settings, where ease of administration and rapid relief are critical. The development of innovative delivery systems is expected to diversify product offerings and meet the evolving needs of healthcare providers and patients.
• Integration of Digital Technologies and Data Analytics: Digital health tools, including electronic health records, telemedicine, and data analytics, are increasingly being integrated into the market. These technologies facilitate personalized treatment plans, real-time monitoring, and improved patient adherence. Data-driven insights help manufacturers optimize formulations, predict market trends, and streamline supply chains. The adoption of digital solutions enhances overall market efficiency and patient outcomes, while also opening new avenues for marketing and customer engagement. This trend is transforming traditional market dynamics into a more connected and responsive ecosystem.
• Growing Emphasis on Regulatory Approvals and Quality Standards: Stringent regulatory requirements and quality standards are shaping product development and commercialization strategies. Companies are investing in rigorous clinical trials and compliance measures to meet global standards, ensuring safety and efficacy. This focus on regulatory approval processes influences market entry timelines and product differentiation. Enhanced quality assurance practices build consumer trust and facilitate market expansion across regions with diverse regulatory landscapes. As regulatory scrutiny intensifies, companies that prioritize compliance are better positioned to sustain long-term growth and market credibility.
• Expansion into Emerging Markets: The Granisetron Market is increasingly targeting emerging economies with expanding healthcare infrastructure and rising awareness of antiemetic therapies. Market players are establishing local manufacturing facilities, forming strategic partnerships, and customizing products to meet regional needs. This expansion offers significant growth opportunities due to increasing patient populations and healthcare investments. However, it also presents challenges related to regulatory complexities and market penetration strategies. Overall, entering emerging markets is a key trend that is expected to drive global market growth and diversify revenue streams.

In summary, these trends are collectively reshaping the granisetron base market by enhancing product accessibility, diversifying delivery options, leveraging digital innovations, emphasizing regulatory compliance, and expanding geographic reach. These developments are fostering a more competitive, efficient, and patient-centric market environment, ultimately improving treatment outcomes and broadening the scope of antiemetic therapies worldwide.

Recent Developments in the Granisetron Base Market

The granisetron base market is experiencing significant growth driven by advancements in cancer treatment and the increasing prevalence of chemotherapy-induced nausea and vomiting. As healthcare providers seek more effective antiemetic solutions, the demand for granisetron is rising globally. Innovations in drug formulations and expanding applications in various medical settings are further fueling market expansion. This evolving landscape presents numerous opportunities for manufacturers and stakeholders to capitalize on emerging trends and improve patient outcomes.

• Growing Cancer Incidence and Chemotherapy Use: The rising number of cancer cases worldwide and the widespread use of chemotherapy treatments are boosting demand for antiemetic drugs like granisetron. As chemotherapy regimens become more aggressive, managing nausea and vomiting becomes critical, making granisetron a preferred choice. This increased need directly impacts sales and encourages pharmaceutical companies to invest in research and development for better formulations, expanding market reach and improving patient quality of life.
• Advances in Drug Formulations and Delivery Systems: Innovations in drug delivery, such as transdermal patches and injectable forms, are enhancing the efficacy and convenience of granisetron administration. These advancements improve patient compliance and reduce side effects, making the drug more attractive to healthcare providers. The development of sustained-release formulations also prolongs therapeutic effects, reducing dosing frequency. Such innovations are expected to expand market share and open new avenues for growth within the antiemetic segment.
• Expansion into Emerging Markets: Increasing healthcare infrastructure and rising awareness about cancer treatments in emerging economies are creating new opportunities for granisetron. Governments and healthcare providers are investing in better supportive care, which includes antiemetics. Market players are entering these regions through partnerships and local manufacturing, leading to increased accessibility and affordability. This expansion significantly contributes to global market growth and diversifies revenue streams for pharmaceutical companies.
• Regulatory Approvals and Strategic Collaborations: Recent approvals by regulatory authorities for new formulations and indications are bolstering market confidence. Strategic collaborations between pharmaceutical companies and research institutions facilitate innovation and faster product development. These partnerships also help in navigating regulatory landscapes and expanding distribution networks. Such developments accelerate market penetration and foster a competitive environment, ultimately benefiting patients through improved treatment options.
• Increasing Focus on Personalized Medicine: The shift towards personalized treatment approaches is influencing granisetron market dynamics. Tailoring antiemetic therapy based on genetic and clinical profiles enhances effectiveness and minimizes adverse effects. This trend encourages the development of targeted formulations and combination therapies. As personalized medicine gains traction, the market is poised for growth through customized solutions that improve patient outcomes and reduce healthcare costs, further strengthening the market position of granisetron.

Overall, these developments are significantly impacting the granisetron base market by expanding its application scope, improving drug delivery, and increasing accessibility. The market is poised for sustained growth driven by technological innovations, strategic collaborations, and rising global demand for effective antiemetic therapies. This evolution ultimately benefits patients, healthcare providers, and industry stakeholders alike.

Strategic Growth Opportunities in the Granisetron Base Market

The granisetron base market is experiencing significant growth driven by increasing demand for effective antiemetic solutions in chemotherapy, radiation therapy, and surgical procedures. Advances in pharmaceutical formulations and expanding applications across healthcare sectors are creating new opportunities for manufacturers. As the global healthcare infrastructure improves, the market is poised for further expansion, supported by rising awareness of supportive cancer care and the need for targeted therapies. Strategic investments and innovation will be crucial for capturing market share and meeting evolving patient needs.

• Expanding Use in Chemotherapy-Induced Nausea and Vomiting Management: Granisetron is widely used to prevent nausea and vomiting caused by chemotherapy, making it essential in cancer treatment protocols. The rising prevalence of cancer globally and the increasing adoption of supportive care measures are boosting demand. Pharmaceutical companies are developing new formulations to improve efficacy and patient compliance, further expanding their application scope. This growth is driven by the need for effective, targeted antiemetic therapies that enhance patient quality of life during treatment.
• Growing Adoption in Radiation Therapy and Surgical Procedures: The use of granisetron in managing nausea associated with radiation therapy and post-surgical recovery is increasing. As radiation techniques become more prevalent and surgical interventions expand, the demand for antiemetics like granisetron rises. Hospitals and clinics are prioritizing supportive care to reduce treatment-related side effects, leading to increased prescriptions. Innovations in drug delivery systems and combination therapies are expected to further enhance its market penetration in these areas.
• Rising Demand for Long-Acting and Transdermal Formulations: The development of long-acting and transdermal granisetron formulations aims to improve patient convenience and adherence. These formulations reduce dosing frequency and eliminate the need for injections, making them suitable for outpatient settings. The focus on patient-centric care and minimally invasive options is driving research and development in this segment. As regulatory approvals are obtained, these innovative formulations are expected to significantly expand market share and improve treatment outcomes.
• Increasing Focus on Personalized Medicine and Combination Therapies: Personalized treatment approaches are shaping the future of antiemetic therapy, with granisetron being integrated into combination regimens tailored to individual patient profiles. Pharmacogenomics and biomarker research are enabling more precise dosing and therapy customization. This trend enhances efficacy and reduces adverse effects, encouraging broader adoption. The integration of granisetron into multi-drug protocols aligns with the shift toward personalized medicine, opening new avenues for market growth and improved patient care.
• Rising Investment in Research and Development for New Indications: Ongoing R&D efforts aim to explore new therapeutic indications for granisetron beyond its current use. Researchers are investigating its potential in managing nausea related to other medical conditions, such as postoperative recovery and certain gastrointestinal disorders. Increased funding from pharmaceutical companies and academic institutions is accelerating innovation. These developments could diversify the application base, expand market opportunities, and reinforce granisetron's role as a versatile antiemetic agent in various healthcare settings.

The overall impact of these opportunities is set to significantly enhance the granisetron base market, fostering innovation, expanding application areas, and improving patient outcomes. Strategic focus on formulation development, personalized therapies, and new indications will be key drivers of sustained growth and market competitiveness in the coming years.

Granisetron Base Market Driver and Challenges

The granisetron base market is influenced by a variety of technological, economic, and regulatory factors that shape its growth trajectory. Advances in pharmaceutical manufacturing and delivery systems enhance drug efficacy and patient compliance, while economic conditions impact healthcare spending and drug affordability. Regulatory policies, including approvals and safety standards, also play a crucial role in market expansion or contraction. Additionally, increasing awareness of chemotherapy-induced nausea and vomiting (CINV) management drives demand for Granisetron. However, challenges such as stringent regulatory hurdles, high R&D costs, and market competition pose significant barriers. Understanding these drivers and challenges is essential for stakeholders to navigate the evolving landscape effectively.

The factors responsible for driving the granisetron base market include:

• Technological Advancements: The development of novel drug delivery systems, such as transdermal patches and injectable formulations, improves drug bioavailability and patient compliance. Innovations in manufacturing processes reduce production costs and enhance drug stability, making Granisetron more accessible. These technological improvements enable faster market penetration and support the development of combination therapies, expanding the market scope. As research continues, new formulations are expected to further boost demand, especially in oncology settings where effective management of CINV is critical.
• Rising Prevalence of Cancer: The increasing incidence of cancer worldwide, particularly in developing regions, significantly drives the demand for antiemetic therapies like Granisetron. As more patients undergo chemotherapy, the need for effective nausea and vomiting management grows. This trend is supported by aging populations and lifestyle factors contributing to cancer prevalence. The expanding patient base ensures sustained demand for Granisetron, encouraging manufacturers to increase production and invest in marketing efforts to meet the rising need.
• Regulatory Approvals and Support: Stringent regulatory frameworks and approvals from agencies such as the FDA and EMA facilitate market entry and ensure drug safety and efficacy. Positive regulatory decisions can accelerate product launches and expand market access across different regions. Additionally, government initiatives promoting cancer treatment and supportive policies for pharmaceutical innovation further bolster market growth. Compliance with regulatory standards also enhances brand credibility, encouraging healthcare providers to prescribe Granisetron more confidently.
• Growing Healthcare Infrastructure: Improvements in healthcare infrastructure, especially in emerging economies, enable better diagnosis and treatment of cancer patients. Increased healthcare spending, availability of specialized oncology centers, and trained medical professionals contribute to higher adoption rates of Granisetron. This infrastructure development ensures that more patients receive appropriate antiemetic therapy, thereby expanding the market. Moreover, collaborations between pharmaceutical companies and healthcare providers facilitate wider distribution and awareness of Granisetron products.
• Strategic Collaborations and Market Expansion: Partnerships between pharmaceutical companies, research institutions, and healthcare organizations foster innovation and facilitate market expansion. Licensing agreements, mergers, and acquisitions enable companies to access new markets and diversify their product portfolios. These collaborations also support clinical research, leading to improved formulations and indications for Granisetron. As companies focus on expanding their geographic reach, especially in untapped markets, the overall market growth is stimulated through increased availability and awareness.

The challenges facing the granisetron base market include:

• Stringent Regulatory Hurdles: Navigating complex regulatory requirements across different regions can delay product approvals and increase costs. Ensuring compliance with safety, efficacy, and manufacturing standards demands extensive clinical trials and documentation, which can be time-consuming and expensive. These hurdles may restrict market entry for new players and limit the availability of innovative formulations, thereby impacting overall market growth.
• High R&D and Manufacturing Costs: Developing new formulations or improving existing ones requires significant investment in research and development. Manufacturing high-quality Granisetron involves sophisticated technology and strict quality controls, leading to high operational costs. These financial burdens can deter smaller companies from entering the market and may result in higher prices for end-users, potentially limiting accessibility and adoption.
• Market Competition and Patent Expirations: The presence of multiple established players and generic manufacturers intensifies competition, leading to price wars and reduced profit margins. Patent expirations of key formulations open the market to generic versions, which are often priced lower but may impact brand loyalty and revenue streams for original manufacturers. This competitive landscape necessitates continuous innovation and strategic marketing to maintain market share, posing ongoing challenges for companies.

In summary, the granisetron base market is driven by technological innovations, rising cancer prevalence, supportive regulatory environments, improved healthcare infrastructure, and strategic collaborations. However, it faces challenges such as regulatory complexities, high R&D costs, and intense market competition. These factors collectively influence the markets growth potential, requiring stakeholders to adapt strategies accordingly. While expansion opportunities exist, addressing the challenges effectively will be crucial for sustained success in this evolving landscape.

List of Granisetron Base Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies granisetron base companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the granisetron base companies profiled in this report include-

• Wavelength Pharmaceuticals
• Kyowa Kirin
• Heron Therapeutics
• Fresenius Kabi
• Hikma Pharmaceuticals
• Teva
• Cipla
• Sandoz
• Wockhardt
• Mylan

Granisetron Base Market by Segment

The study includes a forecast for the global granisetron base market by type, application, and region.

Granisetron Base Market by Type [Value from 2019 to 2035]:

• Capsule
• Pill

Granisetron Base Market by Application [Value from 2019 to 2035]:

• Hospital
• Pharmacy

Granisetron Base Market by Region [Value from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Granisetron Base Market

The granisetron base market has experienced notable shifts driven by advancements in pharmaceutical research, regulatory changes, and evolving healthcare needs across major economies. As the demand for effective antiemetic treatments grows, countries are investing in new formulations, expanding manufacturing capacities, and enhancing distribution channels. These developments reflect a broader trend toward improving cancer care and managing chemotherapy-induced nausea and vomiting. The competitive landscape is also evolving with increased collaborations and technological innovations, aiming to meet the rising global demand. Understanding these regional dynamics is crucial for stakeholders aiming to capitalize on emerging opportunities in the granisetron base market.

• United States: The US market has seen significant growth due to increased cancer prevalence and advancements in drug delivery systems. Regulatory agencies like the FDA have approved new formulations, including extended-release versions, improving patient compliance. The focus on clinical trials for combination therapies is also rising, aiming to enhance efficacy. Moreover, the expansion of healthcare infrastructure and insurance coverage has facilitated wider access to Granisetron treatments. The presence of key pharmaceutical players and ongoing research initiatives continues to drive innovation and market expansion in the United States.
• China: China's Granisetron market is rapidly expanding, fueled by a rising cancer burden and government initiatives to improve oncology care. Local manufacturers are investing in R&D to develop cost-effective formulations, increasing market competitiveness. The government's approval of new drugs and supportive policies for pharmaceutical innovation are further boosting growth. Additionally, the growing awareness of chemotherapy side effects and improved healthcare infrastructure are driving demand. The increasing adoption of generic versions has made treatments more affordable, broadening access across urban and rural areas.
• Germany: Germany's market benefits from a well-established healthcare system and high healthcare expenditure. The country emphasizes the development of advanced formulations, including injectable and oral forms, to improve patient outcomes. Regulatory bodies maintain strict standards, ensuring high-quality products. Germany also sees a rise in clinical research activities focused on combination therapies involving Granisetron. The presence of major pharmaceutical companies and collaborations with research institutions foster innovation. Additionally, increasing awareness about managing chemotherapy side effects contributes to steady market growth.
• India: India's Granisetron market is characterized by rapid growth driven by a large patient population and increasing cancer cases. The affordability of generic formulations has made treatment accessible to a broader demographic. Government initiatives to improve healthcare infrastructure and cancer care facilities are supporting market expansion. Local manufacturers are focusing on cost-effective production and distribution channels to meet rising demand. The growing prevalence of chemotherapy treatments and awareness campaigns about managing side effects is further propelling market growth. The market is also witnessing increased imports of advanced formulations to meet domestic needs.
• Japan: Japan's market is driven by an aging population and a high incidence of cancer, leading to increased demand for antiemetic drugs like Granisetron. The country emphasizes the development of innovative formulations with improved efficacy and reduced side effects. Regulatory agencies are supportive of clinical research, fostering innovation. Japan's healthcare system's focus on personalized medicine and advanced treatment protocols is influencing market dynamics. The presence of leading pharmaceutical companies and collaborations with research institutions contribute to ongoing advancements. Rising awareness about supportive care in oncology is also fueling market growth in Japan.

Features of the Global Granisetron Base Market

• Market Size Estimates: Granisetron base market size estimation in terms of value ($M).
• Trend and Forecast Analysis: Market trends (2019 to 2025) and forecast (2026 to 2035) by various segments and regions.
• Segmentation Analysis: Granisetron base market size by type, application, and region in terms of value ($M).
• Regional Analysis: Granisetron base market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the granisetron base market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the granisetron base market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the granisetron base market by type (capsule and pill), application (hospital and pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Granisetron Base Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Capsule : Trends and Forecast (2019-2035)
• 4.4 Pill : Trends and Forecast (2019-2035)

5. Global Granisetron Base Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital : Trends and Forecast (2019-2035)
• 5.4 Pharmacy : Trends and Forecast (2019-2035)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Granisetron Base Market by Region

7. North American Granisetron Base Market

• 7.1 Overview
• 7.2 North American Granisetron Base Market by Type
• 7.3 North American Granisetron Base Market by Application
• 7.4 The United States Granisetron Base Market
• 7.5 Canadian Granisetron Base Market
• 7.6 Mexican Granisetron Base Market

8. European Granisetron Base Market

• 8.1 Overview
• 8.2 European Granisetron Base Market by Type
• 8.3 European Granisetron Base Market by Application
• 8.4 German Granisetron Base Market
• 8.5 French Granisetron Base Market
• 8.6 Italian Granisetron Base Market
• 8.7 Spanish Granisetron Base Market
• 8.8 The United Kingdom Granisetron Base Market

9. APAC Granisetron Base Market

• 9.1 Overview
• 9.2 APAC Granisetron Base Market by Type
• 9.3 APAC Granisetron Base Market by Application
• 9.4 Chinese Granisetron Base Market
• 9.5 Indian Granisetron Base Market
• 9.6 Japanese Granisetron Base Market
• 9.7 South Korean Granisetron Base Market
• 9.8 Indonesian Granisetron Base Market

10. ROW Granisetron Base Market

• 10.1 Overview
• 10.2 ROW Granisetron Base Market by Type
• 10.3 ROW Granisetron Base Market by Application
• 10.4 Middle Eastern Granisetron Base Market
• 10.5 South American Granisetron Base Market
• 10.6 African Granisetron Base Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Granisetron Base Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Wavelength Pharmaceuticals
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Kyowa Kirin
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Heron Therapeutics
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Fresenius Kabi
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Hikma Pharmaceuticals
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Teva
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Cipla
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Sandoz
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Wockhardt
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Mylan
  • Company Overview
  • Granisetron Base Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us